Efficacy and Safety of Culmerciclib Plus Aromatase Inhibitors in a Response-Adapted Neoadjuvant Strategy for Highly Proliferative ER-Positive/HER2-Negative Breast Cancer

​ Conditions: HR+/HER2- Early Breast Cancer

Interventions: Drug: Culmerciclib; Drug: Aromatase Inhibitors

Sponsors: Second Affiliated Hospital, School of Medicine, Zhejiang University

Recruiting Conditions: HR+/HER2- Early Breast Cancer
Interventions: Drug: Culmerciclib; Drug: Aromatase Inhibitors
Sponsors: Second Affiliated Hospital, School of Medicine, Zhejiang University
Recruiting